Business Wire

MA-ECHOSENS

Share
Leading Liver Disease Researchers Present at EASL International Liver Congress™ 2021, Demonstrate Prognostic Value of Echosens’ FibroScan-based Agile Scores for Patients with Liver Disease

Echosens , a high-technology company offering the FibroScan family of products, today announces that distinguished researchers will present studies supporting the value of FibroScan at EASL’s International Liver Congress , June 23-26, 2021. An area of focus will be FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients.

“Agile scores were built on a large and global pool of patient data and have been externally validated on two large cohorts of patients—one from France and one from the United States—to achieve this exceptional level of score development,” says Dominique Legros, Group CEO, Echosens. “These novel, noninvasive scores reduce the number of false positive cases compared to liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE™) alone, accurately predict liver complications and, in coming years, will identify patients eligible for pharmaceutical treatments.”

Currently available noninvasive tests, including FIB-4 and LSM by VCTE, are highly effective in excluding cirrhosis and advanced fibrosis, but their ability to rule them in is moderate. Agile 3+ can improve the identification of advanced fibrosis among patients with NAFLD and may reduce the necessity of liver biopsy in this patient population. Agile 4 improves the identification of cirrhotic patients and may reduce the need for liver biopsy for this diagnostic target, as well as identify patients for hepatocellular carcinoma and esophageal varices screening.

Mazen Noureddin, M.D., director, Fatty Liver Program, Cedars-Sinai Medical Center, who will present “Modeling regional variation in the return on investment of VCTE for fatty liver disease (FLD) in the U.S.” at the Congress, states, “Broad deployment of VCTE devices, like FibroScan, is a financially advantageous solution to address the fatty liver disease (FLD) epidemic, with the South and Midwest regions standing to benefit the most, likely due to a combination of the higher prevalence rates of FLD and relevant comorbidities, as well as medical utilization and costs.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

Link:

ClickThru

Social Media:

https://www.facebook.com/fibroscan.echosens

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting styrker sin tilstedeværelse inden for cybersikkerhed med 10Guards9.7.2025 23:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin konsulentkapacitet gennem et samarbejde med 10Guards, en serviceorienteret virksomhed med base i Ukraine, som har specialiseret sig i at levere en bred vifte af professionelle tjenester uden at tilbyde produkter (det være software eller hardware). 10Guards blev stiftet i 2017 og tilbyder skræddersyede cybersikkerhedstjenester, herunder compliance audits, gap assessments og strategisk rådgivning med henblik på at styrke sikkerhedspositionen. De leverer også outsourcet cybersikkerhedssupport gennem virtuelle CISO'er og fulde virtuelle teams, optimering af sikkerhedsdriftscentre (SOC'er) for mere effektiv trusselsdetektering og -respons og etiske hackingtjenester som penetrationstest, social engineering-simuleringer og applikationssikkerhedsvurderinger på tværs af web-, mobil- og cloudmiljøer. "I dagens digitale miljø er cyberresiliens ikke et tilvalg – det er en forudsætning," siger Vitaliy Yakushev, administrerende direktør for 10Guards. "Vores mål er at

IFF to Release Second Quarter 2025 Results on Aug. 5, 20259.7.2025 22:15:00 CEST | Press release

IFF (NYSE:IFF) today announced that it will release its second quarter 2025 earnings results following the market close on Tuesday, Aug. 5, 2025. The management team will host a live webcast on Wednesday, Aug. 6, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20250709408179/en/

Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 18:07:00 CEST | Press release

The winners will be announced 21 January at SPIE Photonics West Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, streng

SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division9.7.2025 17:45:00 CEST | Press release

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”). The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025. Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implan

LambdaTest Enables Playwright Testing on iOS Real Devices to Enhance Mobile Test Accuracy9.7.2025 17:00:00 CEST | Press release

New capability enables QA teams to automate Playwright scripts on real iPhones and iPads for unmatched mobile testing precision LambdaTest, a GenAI-powered quality engineering platform, has announced support for Playwright testing on real iOS devices, enabling mobile web teams to run automated tests on actual iPhones and iPads using Safari. This update helps QA and engineering teams validate user experiences with far greater accuracy than simulators or emulators can offer. Testing mobile web apps on virtual environments often leads to discrepancies in real-world behavior such as missed touch interactions, inconsistent browser rendering, and undetected performance bottlenecks. LambdaTest now eliminates that uncertainty by allowing developers to execute Playwright tests on physical iOS devices. While Playwright itself does not natively support real iOS hardware, LambdaTest’s integration bridges that gap, providing seamless access to Apple’s Safari browser on real devices. Users can integ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye